How I treat relapsed and/or refractory multiple myeloma
The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylas...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Hematology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8955 |
| _version_ | 1828045834690756608 |
|---|---|
| author | Hans C. Lee Claudio Cerchione |
| author_facet | Hans C. Lee Claudio Cerchione |
| author_sort | Hans C. Lee |
| collection | DOAJ |
| description | The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylase inhibitors, and/or alkylating agents. More recently, the approval of the first-in-class nuclear export inhibitor selinexor and the first-in-class B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) belantamab mafodotin has helped address the current unmet need in patients refractory to PI, IMiD, and anti-CD38 mAb directed therapy, otherwise known as triple class refractory myeloma. With the growing number of treatment options in the RRMM therapeutic landscape, the choice and sequencing of drugs and combinations has become increasingly complex. In this review we discuss our approach and considerations in the treatment of both early and late RRRM based on best available data and our clinical experience. |
| first_indexed | 2024-04-10T18:17:35Z |
| format | Article |
| id | doaj.art-07b2a7784cc04966b01ccc6030ece16a |
| institution | Directory Open Access Journal |
| issn | 2038-8322 2038-8330 |
| language | English |
| last_indexed | 2024-04-10T18:17:35Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hematology Reports |
| spelling | doaj.art-07b2a7784cc04966b01ccc6030ece16a2023-02-02T08:06:56ZengMDPI AGHematology Reports2038-83222038-83302020-09-0112s110.4081/hr.2020.8955How I treat relapsed and/or refractory multiple myelomaHans C. Lee0Claudio Cerchione1The University of Texas MD Anderson Cancer Center, Department of Lymphoma/MyelomaHematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC)The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylase inhibitors, and/or alkylating agents. More recently, the approval of the first-in-class nuclear export inhibitor selinexor and the first-in-class B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) belantamab mafodotin has helped address the current unmet need in patients refractory to PI, IMiD, and anti-CD38 mAb directed therapy, otherwise known as triple class refractory myeloma. With the growing number of treatment options in the RRMM therapeutic landscape, the choice and sequencing of drugs and combinations has become increasingly complex. In this review we discuss our approach and considerations in the treatment of both early and late RRRM based on best available data and our clinical experience.https://www.pagepress.org/journals/index.php/hr/article/view/8955Multiple myeloma; Relapsed; Refractory |
| spellingShingle | Hans C. Lee Claudio Cerchione How I treat relapsed and/or refractory multiple myeloma Hematology Reports Multiple myeloma; Relapsed; Refractory |
| title | How I treat relapsed and/or refractory multiple myeloma |
| title_full | How I treat relapsed and/or refractory multiple myeloma |
| title_fullStr | How I treat relapsed and/or refractory multiple myeloma |
| title_full_unstemmed | How I treat relapsed and/or refractory multiple myeloma |
| title_short | How I treat relapsed and/or refractory multiple myeloma |
| title_sort | how i treat relapsed and or refractory multiple myeloma |
| topic | Multiple myeloma; Relapsed; Refractory |
| url | https://www.pagepress.org/journals/index.php/hr/article/view/8955 |
| work_keys_str_mv | AT hansclee howitreatrelapsedandorrefractorymultiplemyeloma AT claudiocerchione howitreatrelapsedandorrefractorymultiplemyeloma |